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The activity of the light (L) chain of tetanus toxin, and of mutants constructed by site-directed mutagenesis, was studied by expression and 
purification of the proteins from E coli. Wild-type recombinant L chain (pTet87) was active m the mhlbitlon of exocytosis from cultured bovine 
adrenal chromaffin cells, although at a level 5--15% of that of L chain purified from tetanus toxin. L chain mutants which terminated at Leu-438 
(pTet89). or which contained a Cys-to-Ser mutation at residue 439 (pTet88) were equally as active as the full-length recombmant protem. The 
reduced activity of pTet87 L chain correlated with C-terminal proteolysls of the protein upon purification. A tryptic fragment derived from native 
light chain and which terminated at Leu-434 also showed reduced activity in the exocytoals assay. consistent with a requirement of the C-terminal 
region of the L chain for maximal activity. pTet87 L cham, but neither of the mutants, could be associated with purified H (heavy) chain to form 
a covalent dimer which induced the symptoms of tetanus in mice. The ablhty to form biologically active toxin using recombinant L chain WIII be 
of great value in structure-function studies of tetanus toxin. 
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1. INTRODUCTION 
Tetanus toxin, produced by Clostridium tetuni, causes 
spastic paralysis by blocking transmitter release at in- 
hibitory synapses. The toxin is synthesized as a single 
150 kDa polypeptide chain which is cleaved by a host 
protease to produce a di-chain molecule, with a dis- 
ulphide bond between the N-terminal 50 kDa light (L) 
chain and the 100 kDa C-terminal heavy (H) chain [l]. 
Neurotoxicity in animals requires the entire toxin, as 
none of the purified chains exhibits toxicity. The toxin 
is considered to act in three distinct steps; binding to a 
cell-surface receptor, internalization, and finally inhibi- 
tion of neurotransmitter release (for a review see [2]). 
The H chain is involved in the binding to sensitive cells 
through ganglioside [3] and perhaps proteinaecous re- 
ceptors [4]. The L chain alone is sufficient to block 
neurotransmitter release, if injected into neurones or 
brought into the cytosol through a permeabilized mem- 
brane [5-71. Recent data indicate that the L chain has 
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a zinc-dependent protease activity [8,9]. It cleaves syn- 
aptobrevin [lo], one component of the pre-synaptic ves- 
icles. Possibly this enzymatic activity is responsible for 
the pharmacological action of the toxin. 
The intracellular activity of purified tetanus toxin L 
chain was first demonstrated using permeabilized chro- 
maffin cells [5] and injected Ap/~~iu neurones [7]. The 
activities of the L chains of both tetanus and botulinurn 
toxins have also been studied in Apl}‘sicI neurones using 
micro-injection of mRNA encoding the relevant pro- 
teins [l 11. These experiments showed a reduction in the 
post-synaptic response after injection of mRNA encod- 
ing tetanus L chain, demonstrating that the translated 
products were responsible for the inhibition of transmit- 
ter release [l 11. 
We have previously described the use of bacterial 
expression systems for the production of immunogenic 
fragments of tetanus toxin which have application in 
vaccine development [ 121. In this paper, we describe the 
construction, expression and characterization of recom- 
binant forms of derivatives of tetanus toxin L chain 
from E. co/i. We demonstrate that purified recombinant 
L chain inhibits exocytosis in bovine adrenal cells and 
can form biologically active toxin when associated with 
purified H chain. 
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2. MATERIALS AND METHODS 
2.1. Materials 
Restriction endonucleases and DNA-modifying enzymes were ob- 
tamed from Boehringer-Mannheim and were used as recommended 
by the manufacturer. [a-%]dATP and the in vitro site-directed mut- 
agenesis kit were supplied by Amersham, UK. Chromatography col- 
umns were from Pharmacia, Freiburg, Germany. 
2.2. Recombinant DNA techniques 
Escherichia coli K-12 strain TGl was used throughout this work. 
DNA encoding tetanus toxin was derived from pTet20 [13]. which 
contains a 1.6 kb HindIII-EcoRI fragment encoding the L chain and 
part of the H chain of tetanus toxin. A stop codon was inserted at the 
C-terminus of the L chain in pTet20 after Ala-457 by site-directed 
mutagenesis using the oligonucleotide 5’-TCCTCCTAAATCTGTT- 
TATCATGCAGTTCTATTAT-3’. The resulting 1.6 kb EcoRI- 
Hind111 fragment was cloned into pUC19 so that the expression of 
the L chain was under the control of the lac promoter. Oligonucleo- 
tides, S’CGATGGATCCAITTTAATTAGGAGATGATACGTAT- 
GCIGCAGAATTCCG-3’ and S-GATCCGGAATTCTGCAGCA- 
TCATACGTATCATCTCCTAATTAAAATGGATCCAT-3’. were 
cloned into Bluescript SKII’ to facilitate the cloning of a 1.6 kb 
SnaBI-EcoRI L chain fragment to form pTet86. The resulting 1.6 kb 
BarnHI fragment was then cloned into pTETtacl15 cut with BumHI 
and BglII to form pTet87. Similarly, oligonucleotides were used to 
change Cys-439 to either Ser-439 (pTet89) or to a stop codon (pTet88). 
Recombinant DNA techniques were performed as described by Mani- 
atis et al. [14]. The DNA sequence of all mutants was confirmed by 
direct DNA sequencing of plasmids. 
2.3. Expression and purification of recombmant proteins 
E. coli cells containing plasmids were grown overnight in L-broth 
[14] with ampicillin (100 &ml). Cells were diluted 1 in 5 into fresh 
medium containing 60 @ml isopropyl-thio-galactopyranoside 
(IPTG) and grown for 4 h to an AsSO of approximately 2.0. Cells from 
2 1 of culture were harvested by centrifugation, washed m buffer 1 (50 
mM Tris-HCl, pH 7.5.50 mM NaCI) and resuspended in 20 ml buffer 
1 containing 10 mM benzamidine and 1 .O@ml DNase. The cells were 
then lysed by double passage through a pre-cooled French pressure 
cell (15,000 lb.m.-‘). DTT, EDTA and PMSF were each added to final 
concentrations of 1 mM, and intact cells were removed by centrifuga- 
tion (10,000 x g, 10 min). The lysate (20 ml) was then stored at -70°C 
before purification. 
Lysate (556 ml) was mixed with an equal volume of buffer (40 mM 
piperazine-HCl, 2 M ammomum sulphate, 1 mM DTT, pH 5.8). 
stirred at 4°C for 30 min and centrifuged (50,000 x g, 30 min. 4°C). 
After filtration through a 0.2 pm filter, the supernatant was loaded on 
to a phenyl-Sepharose HP 16/10 column. Fractions were eluted with 
a gradient of 40 mM piperazine-HCI, pH 5.8, 2 M urea, 1 mM DTT, 
and tested for L chain immune reactivity by SDS-PAGE and Western 
blotting. Positive fractions were pooled, dialysed against 30 mM bis- 
Tris-HCI, 1 mM DTT, pH 5.8, and loaded on to a MonoQ IO/10 
column equilibrated with the same buffer. The column was eluted with 
a linear gradient of 300 mM NaCl m 30 mM his-Tris-HCl, pH 5.8, 1 
mM DTT. Fractions containing L chain were pooled and mixed with 
an equal volume of buffer (100 mM sodium phosphate, 2.5 M ammo- 
nium sulphate, 1 mM DTT, pH 5.8) and applied to an alkyl-Superose 
5/5 column equilibrated with 50 mM sodium phosphate, 1.25 M am- 
monium sulphate, 1 mM DTT, pH 5.8. The column was eluted with 
a linear gradient of 50 mM sodium phosphate, pH 5.8. The yield of 
purified L chain was 1-2 mg/l culture, L cham purified from toxin and 
subjected to these purification steps retained full activity. 
2.4. [-‘H]Noradrenaline release from digitonin-permeabdized adreno 
medullary cells 
Chromaffin cells from bovine adrenal medulla were cultured, pre- 
loaded with [3H]noradrenaline, permeabilized with digitonin and mcu- 
bated with L chain preparations or with potassium glutamate buffer 
alone [5,9]. The Ca’+-stimulated release of [3H]noradrenaline was 
measured m the presence of ATP [5,9]. 
2.5. Association of H and L chains and determination of ioxlcity 
Native chains of tetanus toxin were isolated and purified from 
tetanus toxin [15]. Purified H chain was mixed with equimolar 
amounts of native or recombinant L cham, and reconstitution of toxin 
was attempted by overnight incubation at 4°C against 50 mM Tris. 
600 mM glycine, pH 8.4 [15]. The LD,, of the mixtures was determined 
[I61 and formation of covalently linked heterodimers was assessed by 
SDS-PAGE under non-reducing conditions [15]. 
2.6. Trypsrn digestion of L chain of tetanus toxin 
Purified L chain (6 mg/ml) was digested with trypsin (E.C. 3.4.21.4) 
at an enzyme:substrate ratio of 1:200 at 37°C for 1 h. Protease activity 
was then blocked by diisopropylfluorophosphate (1 mM). Cleavage 
products were purified by HIC on alkyl-Superose 5/5 (see section 2.3.) 
and treated with BrCN followed by C,, reverse phase HPLC. Peaks 
appearing de novo in the peptide pattern were collected [19] and 
subjected to Edman degradation using a Pulsed Liquid Phase 
ABI477A sequencer. 
3. RESULTS 
Synthesis of the L chain of tetanus toxin in E. coli was 
achieved by using a clone (pTet20) which encodes the 
entire L chain and part of the H chain [13]. A stop 
codon was introduced by site-directed mutagenesis in 
order to make Ala-457 the C-terminal amino acid of the 
recombinant L chain (see Fig. 1). To obtain expression 
of the L chain, the gene was cloned into pTETtac115, 
a construct we have used previously for the high-level 
expression of tetanus toxin fragment C [12]. The result- 
ing plasmid (pTet87) expresses the L chain using the 
ribosome binding site from the E. coli trpE gene, rather 
than those of tetanus toxin. Two derivatives of pTet87 
were constructed by site-directed mutagenesis: pTet88 
which has a stop codon introduced in place of Cys-439, 
and pTet89 in which Cys-439 was changed to Ser (see 
Fig. 1). 
E. coli containing plasmids pTet87, 88 and 89 were 
grown and induced for the synthesis of L chain. Fig. 2 
shows that all strains produce a protein which reacts 
with monoclonal antibody specific for L chain. pTet87 
and pTet89 both give bands of molecular weight ap- 
proximately equal to native L chain, whereas pTet88, 
which is 19 amino acids shorter (Fig. 1) produces a band 
Fig. 1. Predicted C-terminal amino acid sequence of the recombinant 
L chain proteins. and the determined C-terminal sequence of trypsi- 
nized L chain. The absence of the Met residue before Pro-2 was 
confirmed m pTet87 (see text). The sequence between Pro-2 and Lys- 
434 is represented by dots (_. ). The C-terminal amino acid of toxin- 
derived L chain is Glu-450 [17]. The Cys-439 residue which was 
changed to Ser is underlined. 
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Fig. 2. Western blot of native and recombinant L chain preparations 
with rabbit anti-L chain sera. Lanes 1, native L cham; 2. E. coli pTet83; 
3, pTet87; 4, pTet88; 5, pTet89. E. cob SDS lysates were prepared from 
freshly grown cells and are shown before purificatron. The arrows 
point to the mature L chain translation products from E. co/l. 
of lower molecular weight. In all strains, proteolytic 
breakdown of the light chain was evident from the ap- 
pearance of several bands of lower molecular weight 
than the mature protein. 
The three recombinant proteins were purified from E. 
coli lysates as described in section 2 (see Fig. 3). SDS- 
PAGE analysis of the different recombinant L chains 
revealed that purified pTet87 protein (Fig. 4, lane 4) had 
increased mobility compared to L chain derived from 
toxin (lane 3); this preparation has previously been 
shown to have Glu-450 as the C-terminal amino acid 
[ 171. Native L chain treated with a control E. coli lysate 
also exhibited increased mobility (lane 6). suggesting the 
presence of protease activity inherent in the E. coli ly- 
sate. This proteolysis could be only partially prevented 
by the addition of high concentrations of the protease 
inhibitors pepstatin and leupeptin (data not shown). 
Purified pTet87, 88 and 89 all exhibited similar mobili- 
ties (lanes 4-6) in contrast to that observed in the E. coli 
lysates (see Fig. 2). This suggests that the originally 
larger proteins (pTet87 and pTet89) have been short- 
ened during cell lysis or purification to derivatives hav- 
ing more similar molecular weights. N-Terminal amino 
acid sequencing of the first 20 amino acids of purified 
pTet87 protein revealed the predicted sequence, starting 
with Pro-2, the first amino acid of native L chain (data 
not shown). Thus it is probable that a proteolytic activ- 
ity in E. coli lysates is acting at the C-terminus of the 
L chain, whether derived from tetanus toxin or from E. 
co/i. Interestingly, L chain purified from L-H, chain ran 
at an intermediate position between native L chain and 
L chain which had been exposed to E. coli lysates (lane 
Fig. 3. 8% SDS-PAGE analysis of the purification of L chain from E 
coli. Lanes 1: E. co/i pTet87 lysate: 2 ammonium sulphate precipita- 
tion; 3, phenyl-Sepharose HP; 4, Mono-Q; 5, alkyl-Superose. Gels 
were run under reducing conditions and were silver stained. Amounts 
of protein loaded are’ lanes 1 and 2, 1 pg; lane 3, 0.5 yg: lanes 4 and 
5, 0.3 ,Ug. 
7). This preparation had the expected N-terminus, 
whereas its C-terminus was shortened by three or four 
amino acids, ending at Thr-446 or Asn-447 [17]. 
To ascertain whether the recombinant L chain re- 
tained biological activity, H chain purified from tetanus 
toxin was mixed with pTet87, pTet88 and pTet89 pro- 
teins purified from E. coli. After dialysis to allow asso- 
ciation of the chains, the mixtures were injected into 
mice. Symptoms of tetanus were seen only in mice in- 
jected with the pTet87-H chain mixture, demonstrating 
12345678 
Fig. 4. Comparison of the molecular weights of L chains from drfferent 
origins. Lanes: 1 and 7. native L chain, 2, fragment L-H, composed 
of L chain (upper band) and H, (lower band): 3, native L cham treated 
with pTet83 lysate; 4. pTet88; 5. pTet89: 6, pTet87; 8, molecular 
weight markers (top to bottom; 94 kDa, 67 kDa. 43 kDa) 
220 
Volume 323, number 3 FEBSLETTERS 
LC from Toxin 
LC from Toxin 
Protein Concentration (nM) 
June 1993 
LC Cleaved by Trypsin 
Protein Concentration (nM) 
Fig. 5. Inhibition of Ca’+-stimulated catecholamine release from digitonin-permeabilized chromaffin cells by recombinant L chain. Permeabilized 
adrenal medullary cells were treated with increasing concentrations of purified preparations of L chain and derivatives in Ca*‘-free buffer for 25 
min at 37°C. (A) L chain from tetanus toxin (+); pTet87 (A); pTet88 (0); pTet89 (0). (B) L chain from tetanus toxin (t); trypsin-treated L chain 
(v). The control value represents the % release observed in the absence of added protein. Control values (0) are evoked release due to 20 ,uM free 
Ca” without addition of L chain and were the mean of triplicate determinations. The data points of L cham and derivatives represent the mean 
of duplicate determinations. Basal (spontaneous release) of 0.9% (A) and 1.5% (B) was subtracted. 
that the recombinant L chain was active as a component 
of biologically active neurotoxin (Table I). No symp- 
toms of tetanus were seen using the pTet88 and pTet89 
mixtures. pTet87 was the only recombinant protein 
which could be shown by SDS-PAGE to form a cova- 
lent heterodimer with the H chain via a disulphide bond. 
These results indicate that the Cys-439 of the L chain 
is essential for reassociation of the L and H chains, and 
that disulphide linkage of separated L and H chains is 
essential for toxicity in vivo. 
The bovine adrenal chromaffin cell system was used 
to study the ability of the L chain preparations to inhibit 
the release of catecholamines. The purified recombinant 
preparations were equally as active as inhibitors of 
transmitter release (Fig. 5A), however, ten times less 
than the native L chain. A similar reduction in potency 
was observed using native L chain, purified from teta- 
nus toxin, which had been treated with a control E. coli 
lysate prior to purification (data not shown). This mod- 
ified L chain, and all the purified recombinant L chains, 
showed increased mobility on SDS-PAGE (Fig. 4). 
As the N-terminal amino acid sequence is conserved, 
increased mobility suggested a loss of C-terminal amino 
acid residues. A comparable degree of shortening, as 
evidenced by increased electrophoretic mobility, was 
achieved by treatment of L chain with high concentra- 
tions of trypsin (Sanders, D., Ph.D. Thesis, GieDen, 
1993). The resulting purified tryptic core protein had an 
unmodified N-terminus. To identify its C-terminus, it 
was cleaved with cyanogen bromide. When compared 
to that of native L chain, the resulting peptide pattern 
displayed a loss of one peptide (#l 1) which starts with 
(417) RVNT and is known to terminate at Glu-450, the 
C-terminus of native L chain [17,19]. A new peptide 
appeared which shared the same N-terminus as peptide 
# 11, however, Edman degradation stopped at Lys-434, 
indicating that this was the C-terminal amino acid. As 
shown in Fig. 5B, this fragment had 10-30 times less 
activity in the adrenal cell system than native L chain, 
consistent with a requirement for amino acid residues 
after Lys-434 for full activity of the L chain in this assay. 
4. DISCUSSION 
Our results demonstrate that it is possible to produce 
active L chain of tetanus toxin in E. coli. Biological 
activity of this protein was demonstrated in two ways: 
(i) association with H chain to produce neurotoxic ac- 
tivity in mice, and (ii) inhibition of catecholamine re- 
lease in permeabilized bovine adrenal cells. In the chro- 
maffin cells, the activity of recombinant pTet87 protein 
Table I 
Association of recombinant L chains with the H chain of tetanus toxin 
Source of L chain Toxicity of reassociated Covalent dimer’ (%) 
chains (LD,,)” 
Nativeb 
Nativei’, trypsinized 
pTet87 
pTet88 
pTet89 
0.1 100 
not tested 0 
6 25 
> 1,000 0 
> 1,000 0 
“H chain from toxin was mixed with equimolar amounts of L chain 
from either toxin or E. coli to associate to holotoxin. Toxicity was 
determined as described [16] and is given as /@kg (mouse). 
H and L chains alone purified from toxin had LD,,s of > 10 &kg. 
bPrepared from tetanus toxin. 
‘Protein present as a covalent dimer (%) was determined by SDS- 
PAGE. 
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was 5-15% that of native L chain. This reduction is 
consistent with C-terminal proteolytic degradation of 
recombinant L chain which was observed upon purifi- 
cation of the protein, and which appeared to involve an 
E. coli requirement for this C-terminal 
region of L chain for maximal activity in the exocytosis 
assay was reinforced by our data showing the reduced 
activity of a trypsin-derived 
degradation at 
this site and could help further define the sequence of 
L chain which is essential for maximum activity of the 
L chain. Production of L chain in protease-deficient 
purification of the 
mature form of this protein and increase its activity. 
The lower activity (60-fold) of holotoxin, formed by 
of purified native H chain and 
L chain pTet87. in contrast to holotoxin formed by 
mixing purified native chains, is striking. This can be 
partially explained by the lower efficiency of 
L chain pTet87 (Table I). Thus the amino acids C- 
terminal to Cys-439 may be important for the associa- 
tion of the chains. In addition, loss of toxicity may also 
be due to the lower potency of the shortened L-chains. 
which is reflected by the lower inhibitory potency of 
exocytosis in vitro. Our results contrast to those ob- 
tained using mRNA encoding various L chain se- 
quences expressed in ApZysia [l 11. In this system, it was 
found that mRNA encoding L chain terminating at 
Thr-392 was still active in depressing the post-synaptic 
response to presynaptic stimuli, whereas we find that 
larger proteins terminating at Leu-438 (pTet88) or at 
Lys-434 (trypsin derived core fragment) have reduced 
activity. Differences between the Aplysia and the bovine 
adrenal cell systems, or the use of mRNA compared to 
purified protein, may account for some or all of these 
differences. However, neither system represents the in 
vivo activity of tetanus toxin, and we think it attractive 
to use mutant toxin derivatives in an animal model. The 
use of recombinant L chain together with toxin-purified 
H chain provides a powerful method for the analysis of 
the effect of site-directed mutations within the L chain 
in vivo. The reassociation of E. coli-derived L chain 
with toxin-derived H chain has demonstrated that dis- 
ulphide linkage of these two chains is essential for in 
vivo toxicity. This supports the conclusions of Schiavo 
et al. [18]. who used reduction of the inter-chain dis- 
ulphide bond to demonstrate a requirement for mouse 
toxicity. 
Our observation that L chain synthesized in E. coli 
can be purified and retains biological activity makes it 
attractive to study further derivatives of L chain-con- 
taining mutations of the histidine residues contained 
within the Zn2’-binding domain, to test the hypothesis 
in animals that Zn”-binding mediated by these amino 
acids is essential for toxin activity. L chain and deriva- 
tives constructed by site-directed mutagenesis purified 
from E. coli can be used to further characterize the 
protease activity now found to be associated with this 
protein [S-lo]. 
Acknonledgentents~ This work was supported by Deutsche 
Forschungsgemeinschaft through SFB 249. We thank Dr. K.D. 
Hungere, Behringwerke. AG, Marburg, for sterile filtered culture su- 
pernatant of C tctam. and Dr. J. Godowac-Zimmermann. Inst. fur 
Physiologische und Pathobiochemie. Johannes Gutenberg Univer- 
sitat, Mainz. and M. Payne, Wellcome Research Laboratories, for 
N-terminal amino acid sequencing. 
REFERENCES 
Ill 
VI 
131 
[41 
[51 
161 
171 
181 
A 
1101 
Ill1 
1121 
1131 
[141 
1151 
[161 
1171 
[181 
[191 
Matsuda, M. and Yoneda, M (1975) Infect. Immun. 12, 11477 
1153. 
Niemann. H. (1991) in. Sourcebook of Bacterial Toxms (Alouf, 
J.E. and Freer, J.H. eds.) pp. 3033348. Academic Press, London. 
van Heymngen. S. (1986) m: International Encyclopedia of Phar- 
macology and Toxicology (Dorner. F. and Drews. J eds.) section 
119. pp. 5499569, Pergamon Press, Oxford. 
Montecucco, C. (1986) Trends Biochem. SCI. 1 I. 314317. 
Ahnert-Hilger, C.. Weller, U.. Dauzenroth. M.-E., Habermann. 
E. and Gratzl, M. (1989) FEBS Lett. 242, 245-248. 
Penner, R.. Neher. E. and Dreyer. F. (1986) Nature 324, 7678. 
Mochida. S., Poulam, B., Weller, U., Habermann, E. and Taut. 
L. (1989) FEBS Lett. 253. 47751. 
Schiavo, G., Poulain, B., Rossetto. O., Befenati, F.. Taut, L. and 
Montecucco. C. (1992) EMBO J. 11, 35774583. 
Sanders. D. and Habermann, E. (1992) Naunyn-Schmiedeberg’s 
Arch. Pharmacol. 346, 3588361 
Schiavo. G., Benfenati. F., Poulam, B., Rossetto. O., Polvermo 
de Laureto, P., DasGupta. B.R. and Montecucco. C. (1992) Na- 
ture 359. 832-835. 
Kurazono, H., Mochida. S., Bmz, T.. Eisel, U., Quanz, M., Gre- 
benstein, O., Wernars, K., Poulam, B.. Taut. L. and Niemann, 
H. (1992) J. Biol. Chem. 267, 14721-14729. 
Makoff, A.J. Ballantine, S.P.. Smallwood, A.E. and Fair- 
weather. N.F. (1989) Bioltechnology 7, 104331046. 
Fairweather. N.F. (1988) in: Anaerobes Today, (Hardie, J.M. 
and Borriello. S.P. eds.) pp. 141-147. Wiley and Sons. Oxford 
Mama& T., Fritsch, E.F. and Sambrook, J. (1982) Molecular 
Cloning: A Laboratory Manual. Cold Spring Harbor Labora- 
tory, NY 
Weller, U., Dauzenroth. M.E., Meyer zu Hermgdorf, D. and 
Habermann. E. (1989) Eur. J. Biochem. 182. 6499656 
Weller, U., Mauler, F. and Habermann. E (1988) Naunyn- 
Schmiedeberg’s Arch. Pharmacol. 338. 99-106. 
Krieglstein. K., Henschen. A.H., Weller, U. and Habermann. E. 
(1991) Eur. J. Biochem. 202, 41-51. 
Schiavo, G., Papmi. E., Genna, G and Montecucco. C. (1990) 
Infect. Immun 58. 41364141. 
Krieglstem, K., Henschen. A, Weller, U. and Habermann, E. 
(1990) Eur. J. Biochem. 188, 3945. 
222 
